humulin i 100units/ml suspension for injection 3ml cartridges
eli lilly and company ltd - insulin isophane human - suspension for injection - 100unit/1ml
novolin n- human insulin injection, suspension
a-s medication solutions - insulin human (unii: 1y17cti5sr) (insulin human - unii:1y17cti5sr) - insulin human 100 [iu] in 1 ml - novolin n is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. novolin n is contraindicated: risk summary available data from published studies over decades have not established an association with human insulin use during pregnancy and major birth defects, miscarriage or adverse maternal or fetal outcomes (see data). there are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see clinical considerations). animal reproduction studies were not performed. the estimated background risk of major birth defects is 6-10% in women with pre-gestational diabetes with a hba1c >7 and has been reported to be as high as 20-25% in women with a hba1c >10. the estimated background risk of miscarriage for the indicated population is unknown. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. clinical considerations diseas
novolin 70/30- human insulin injection, suspension
a-s medication solutions - insulin human (unii: 1y17cti5sr) (insulin human - unii:1y17cti5sr) - insulin human 100 [usp'u] in 1 ml - novolin 70/30 is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. limitations of use: in novolin 70/30, the proportions of short-acting and intermediate-acting insulins are fixed and do not allow for basal versus prandial dose adjustments. novolin 70/30 is contraindicated: risk summary available data from published studies over decades have not established an association with human insulin use during pregnancy and major birth defects, miscarriage or adverse maternal or fetal outcomes (see data). there are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see clinical considerations). animal reproduction studies were not performed. the estimated background risk of major birth defects is 6-10% in women with pre-gestational diabetes with a hba1c >7 and has been reported to be as high as 20-25% in women with a hba1c >10. the estimated background risk of miscarriage for the indicated population is unknown. in the u.s. general
human insulatard penfill 100unitsml suspension for injection 1.5ml cartridges
novo nordisk ltd - insulin isophane human - suspension for injection - 100unit/1ml
caninsulin insulin for dogs and cats
intervet australia pty limited - insulin - parenteral liquid/solution/suspension - insulin hormone active 40.0 iu/ml - endocrine system - cat | dog | bitch | castrate | cat - queen | cat - tom | kitten | puppy - insulin deficiency
humulin i 100 iu/ml suspension for injection
eli lilly and company limited - human insulin (recombinant dna origin) - suspension for injection - 100 iu/ml - insulin (human) - humulin - for the treatment of patients with diabetes mellitus who require insulin for the maintenance of glucose homeostasis
humulin i 100 iu/ml suspension for injection
eli lilly and company limited - human insulin (recombinant dna origin) - suspension for injection - 100 iu/ml - insulin (human) - humulin - for the treatment of patients with diabetes mellitus who require insulin for the maintenance of glucose homeostasis
humulin i kwikpen 100 iu/ml suspension for injection
eli lilly and company limited - human insulin (recombinant dna origin) - suspension for injection - 100 iu/ml - insulin (human) - humulin i - for the treatment of patients with diabetes mellitus who require insulin for the maintenance of glucose homeostasis
humulin m 100 iu/ml suspension for injection
eli lilly and company limited - human insulin (recombinant dna origin) - suspension for injection - 100 iu/ml - insulins and analogues for injection, intermediate- or long-acting combined with fast-acting - humulin m3 - for the treatment of patients with diabetes mellitus who require insulin for the maintenance of glucose homeostasis
humulin m 100 iu/ml suspension for injection
eli lilly and company limited - human insulin (recombinant dna origin) - suspension for injection - 100 iu/ml - insulins and analogues for injection, intermediate- or long-acting combined with fast-acting - humulin m3 - for the treatment of patients with diabetes mellitus who require insulin for the maintenance of glucose homeostasis.